Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaFRA:BA3 -0.70%78 Debt-to-EBITDA is 1.36 as of Jun. 2026, which is 27% below its 10-year median of 1.86. GuruFocus rates FRA:BA3 with a GF Score™ of 78/100 and a GF Value™ of €45.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 478 Medical Devices & Instruments companies, Azenta ranks better than 50.42% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Azenta's Debt-to-EBITDA or its related term are showing as below:
FRA:BA3'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.05 Med: 1.86 Max: 5.15
Current: 1.64
During the past 13 years, the highest Debt-to-EBITDA Ratio of Azenta was 5.15. The lowest was -7.05. And the median was 1.86.
FRA:BA3's Debt-to-EBITDA is ranked better than 50.42% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs FRA:BA3: 1.64
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Azenta Debt-to-EBITDA Related Terms
Azenta Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Azenta's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BA3 vs KMTS, STAA, BLFS: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Azenta's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Azenta's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Azenta (FRA:BA3) has a Debt-to-EBITDA of 1.36 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Azenta. This is 27% below median its historical median of 1.86. According to the industry distribution chart, Azenta ranks #237 out of 478 companies in the Medical Devices & Instruments industry, placing it in the top 49.6%.
Is Azenta's Debt-to-EBITDA too high?
Azenta's current Debt-to-EBITDA of 1.36 is 27% below median its 10-year median of 1.86. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.65. Azenta's value of 1.36 is 17.6% below this industry median. Based on the distribution chart, Azenta ranks #237 out of 478 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's Debt-to-EBITDA compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #237 out of 478 companies for Debt-to-EBITDA. This puts Azenta in the upper half of its industry. The industry median Debt-to-EBITDA is 1.65. Azenta's value of 1.36 is 17.6% below this benchmark. While the company's 10-year median is 1.86 vs. the industry median of 1.65, Azenta has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.65, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Azenta's current Debt-to-EBITDA of 1.36 is 17.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Azenta. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current Debt-to-EBITDA is 1.36, which is 27% below median its own 10-year median of 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (FRA:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.14, compared to a current price of €28.40 — trading 37.1% below its estimated fair value. The current Debt-to-EBITDA is 1.36, which is 27% below median its 10-year median of 1.86 and 17.6% below the Medical Devices & Instruments industry median of 1.65. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Azenta (FRA:BA3), the current Debt-to-EBITDA is 1.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (FRA:BA3) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of €28.40 is trading 37.1% below its estimated GF Value™ of €45.14.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for FRA:BA3:
Debt-to-EBITDA: 1.36 (27% below median its 10-year median of 1.86)
GF Value™: €45.14 vs. price of €28.40 (37.1% below fair value)
Industry Position: 17.6% below the Medical Devices & Instruments median (#237 of 478)
No single metric tells the full story. See the FRA:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for FRA:BA3
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BA3 has been successfully added to your 
